We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+5.08%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.49B
AUM Growth
+$37.4M
Cap. Flow
-$505M
Cap. Flow %
-20.29%
Top 10 Hldgs %
34.18%
Holding
156
New
33
Increased
30
Reduced
32
Closed
28

Top Buys

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$84.9M
2
EHTH icon
eHealth
EHTH
+$41.7M
3
KERX
Keryx Biopharmaceuticals Inc
KERX
+$35.2M
4
AGN
Allergan Inc
AGN
+$34M
5
ITMN
INTERMUNE INC
ITMN
+$26.9M

Top Sells

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$87.6M
2
LH icon
Labcorp
LH
+$56.3M
3
MRK icon
Merck
MRK
+$27.1M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$26.4M
5
DGX icon
Quest Diagnostics
DGX
+$25.5M

Sector Composition

Rank Sector Weight
1 Healthcare 42.33%
2 Financials 2.57%
3 Technology 1.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRS
26
DELISTED
Antares Pharma, Inc.
ATRS
$25.6M 1.03%
9,603,703
+115,242
+1% +$347K
ARNA
27
DELISTED
Arena Pharmaceuticals Inc
ARNA
$25.6M 1.03%
436,907
+315,249
+259% +$19.9M
INSM icon
28
Insmed
INSM
$23.2B
$24.1M 0.97%
1,205,234
-810,913
-40% -$12M
ZLTQ
29
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$23.8M 0.96%
1,566,155
+1,082,635
+224% +$18.5M
QCOR
30
CALL
DELISTED
QUESTCOR PHARMA INC
QCOR
$23.1M 0.93%
250,000
-500,000
-67% -$42.8M
TRIV
31
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$23.1M 0.93%
+1,482,666
New +$22.5M
ELGX
32
DELISTED
Endologix Inc
ELGX
$22.5M 0.91%
148,193
+79,847
+117% +$10.6M
HCA icon
33
HCA Healthcare
HCA
$82.2B
$21.4M 0.86%
+380,189
New +$20.1M
XNPT
34
DELISTED
XENOPORT, INC.
XNPT
$21.4M 0.86%
4,427,642
+42,845
+1% +$182K
ANIP icon
35
ANI Pharmaceuticals
ANIP
$1.77B
$20.9M 0.84%
607,355
+235,783
+63% +$7.39M
AMAG
36
DELISTED
AMAG Pharmaceuticals
AMAG
$20.7M 0.83%
999,339
+464,409
+87% +$8.58M
OFIX icon
37
Orthofix Medical
OFIX
$467M
$19.4M 0.78%
533,812
-57,619
-10% -$1.86M
VNDA icon
38
Vanda Pharmaceuticals
VNDA
$320M
$17.6M 0.71%
1,085,301
+583,592
+116% +$7.77M
IART icon
39
Integra LifeSciences
IART
$1.47B
$17.4M 0.7%
903,883
+399,597
+79% +$7.45M
TRNX
40
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$17.3M 0.69%
739,007
-815,068
-52% -$16.9M
THC icon
41
Tenet Healthcare
THC
$16.7B
$17.2M 0.69%
+366,956
New +$16.6M
PTLA
42
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$17.1M 0.69%
584,848
-185,000
-24% -$4.48M
AGN
43
CALL
DELISTED
Allergan Inc
AGN
$16.9M 0.68%
100,000
– –
AIRM
44
DELISTED
Air Methods Corp
AIRM
$16.1M 0.65%
312,419
-240,125
-43% -$12.2M
ZTS icon
45
CALL
Zoetis
ZTS
$31.9B
$16.1M 0.65%
500,000
– –
BDSI
46
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$16M 0.64%
1,328,300
-2,658,460
-67% -$25.2M
LH icon
47
Labcorp
LH
$23.1B
$15.5M 0.62%
176,333
-649,745
-79% -$56.3M
TPST icon
48
Tempest Therapeutics
TPST
$15.2M
$15.1M 0.61%
564
-8
-1% -$189K
HUM icon
49
Humana
HUM
$47.8B
$14.6M 0.59%
+114,448
New +$13.6M
CI icon
50
Cigna
CI
$75.1B
$14.5M 0.58%
+157,528
New +$13.5M
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2014 Portfolio in Review

As of Q2 2014, Deerfield Management held 156 positions worth $2.49B, up 1.5% from $2.45B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Deerfield Management withdrew a net $505M in Q2 2014, closing 28 positions and reducing 32 holdings. Its most notable exit was Merck, an estimated $27.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, down from 44% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK worth $23.1M.

  • Deerfield Management's largest Q2 2014 buy was TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK: 1,482,666 shares worth $23.1M.
  • Deerfield Management added most to AUXILIUM PHARAMCEUTICALS INC in Q2 2014, an estimated $84.9M increase.
  • Deerfield Management's biggest Q2 2014 reduction was QUESTCOR PHARMA INC, cutting an estimated $87.6M.
  • Deerfield Management fully exited Merck in Q2 2014, selling an estimated $27.1M.
  • Deerfield Management's ten largest holdings make up 34% of its $2.49B portfolio in Q2 2014.
  • Deerfield Management opened 33 new positions and closed 28 in Q2 2014.
  • Deerfield Management's portfolio value rose 1.5% quarter-over-quarter to $2.49B.

Based on Deerfield Management's 13F filing for Q2 2014, filed 14 Aug 2014.